It is important to note that glucose levels may be normal or only marginally raised in patients utilizing SGLT2 inhibitors, leading to euglycemic ketoacidosis, which presents a clinical profile distinct from classical diabetic ketoacidosis. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.